Valeo Pharma Inc VPHIF

Healthcare

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.

GREY:VPHIF - Post by User

Valeo Pharma Inc

<< Previous

Bullboard Posts

Next >>

Post by Betteryear2on Jul 04, 2023 6:04pm

407 Views

Post# 35526421

UPDATE ON OPHTHALMOLOGY BUSINESS UNIT T.VPH

Novartis agrees to sell global rights to XIIDRA® and several other ophthalmology products to Baucsh + Lomb
SIMBRINZA® not included in the divestiture

MONTREAL, July 4, 2023 /CNW/ - Valeo Pharma Inc. (TSX: VPH) (OTCQB: VPHIF) (FSE:VP2) ("Valeo" or the "Company"), a Canadian pharmaceutical company, notes from the news release issued by Novartis on June 30, 2023 that Novartis has agreed to sell XIIDRA®, a prescription eye drop solution indicated for the treatment of the signs and symptoms of dry eye disease, as well as several other ophthalmology products to Bausch + Lomb Corporation. SIMBRINZA® is not part of the products that are being divested by Novartis. The sale is expected to close before the end of the year.

VALEO PHARMA PROVIDES UPDATE ON OPHTHALMOLOGY BUSINESS UNIT (newswire.ca)